Video

Urologists discuss why kidney stones should be considered “a mainstream public health problem”

Author(s):

Urology Times staff

“[Kidney stones] really seems like something that we should be devoting significant resources and effort to trying to figure out the root causes and also better treatments and therapies for,” says Jonathan E. Shoag, MD.

Nevo is chief of endourology at University Hospitals Urology Institute and is an assistant professor of urology at Case Western Reserve University School of Medicine in Cleveland, Ohio. Shoag is a urologist at University Hospitals and an assistant professor of urology at Case Western Reserve University School of Medicine, Cleveland, Ohio.

Related Videos
Wayne Kuang, MD, answers a question during a Zoom video interview
Raveen Syan, MD, FPMRS, answers a question during a Zoom video interview
Mohamad Baker Berjaoui, MD, answers a question during a Zoom video interview
Related Content
FDA greenlights phase 1/2 trial of gene editing therapy for primary hyperoxaluria 1
December 19th 2024

FDA greenlights phase 1/2 trial of gene editing therapy for primary hyperoxaluria 1

Hannah Clarke
The redePHine trial is expected to launch in the first half of 2025.
Why kidney stones will become more prevalent over time
February 17th 2022

Why kidney stones will become more prevalent over time

Urology Times staff
“The prevalence of kidney stones has increased over 80% over the last 30 years, and the epidemiology has changed such that it's beginning at a younger age now,” says Gregory Tasian, MD, MSc, MSCE.
FDA grants rare pediatric disease designation to YOLT-203 for primary hyperoxaluria type 1
September 4th 2024

FDA grants rare pediatric disease designation to YOLT-203 for primary hyperoxaluria type 1

Hannah Clarke
YOLT-203 is currently being assessed in the early phase 1 YOLT-203-101 trial.
Dr. Krambeck investigates efficacy of Trilogy and ShockPulse-SE lithotripters
September 9th 2021

Dr. Krambeck investigates efficacy of Trilogy and ShockPulse-SE lithotripters

Urology Times staff
“You have tradeoffs with every device that you use,” says Amy E. Krambeck, MD.
Increasing thiazide doses linked to fewer kidney stone events
August 27th 2024

Increasing thiazide doses linked to fewer kidney stone events

Hannah Clarke
“What this means for patients is that thiazides remain an important option in the toolkit for preventing kidney stone recurrence,” says Ryan S. Hsi, MD, FACS.
Trial launches of gene editing therapy for primary hyperoxaluria type 1
August 24th 2024

Trial launches of gene editing therapy for primary hyperoxaluria type 1

Hannah Clarke
In total, the trial plans to enroll 7 patients with PH1 through a single center in China.
© 2024 MJH Life Sciences

All rights reserved.